Pragmatic, randomized, multicentric, double-blind, controlled clinicial trial on the treatment of acute gout attacks with prednisolone versus colchicine in primary care (COPAGO)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514738-18-00

Acronym

202102COPAGO

Enrollment

314

Registered

2024-09-20

Start date

2023-01-12

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute gout attack, gout

Brief summary

Most severe pain in the last 24 hours

Detailed description

average response to treatment from day 1 - 6 of follow-up, Swelling and tenderness of the joint, Physical function on day 6 compared to baseline, Overall assessment of the success of treatment by patients, Most severe pain in the last 24 hours, Frequency of use of additional pain medication per treatment group, Frequency of use of non-drug pain therapies in the treatment groups

Interventions

DRUGPlacebo Colchicin

DRUGPREDNISOLONE

DRUGCOLCHICINE

DRUGPlacebo Prednisolon

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Most severe pain in the last 24 hours	—

Secondary

Measure	Time frame
average response to treatment from day 1 - 6 of follow-up, Swelling and tenderness of the joint, Physical function on day 6 compared to baseline, Overall assessment of the success of treatment by patients, Most severe pain in the last 24 hours, Frequency of use of additional pain medication per treatment group, Frequency of use of non-drug pain therapies in the treatment groups	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026